BioPharmSignal logoBioPharmSignal

Biotech News

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

Arbutus (ABUS)ArbutusConference / presentation

Five abstracts accepted for poster presentations WARMINSTER, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that five abstracts, including

Related news

ABUSArbutus2026-10-22 11:30 EST

Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor

ASMBAssembly Biosciences2026-10-05 14:00 EST

Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026

ANTXAN2 Therapeutics2026-11-04 21:00 EST

AN2 Therapeutics to Present at Jefferies Global Healthcare Conference in London

ASMBAssembly Biosciences2026-09-10 20:15 EST

Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference

AVIRAtea2026-09-08 11:00 EST

Atea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

SPROSpero Therapeutics2026-09-02 21:01 EST

Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference

SCYXSCYNEXIS2026-10-29 12:00 EST

SCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation Conference

SPROSpero Therapeutics2026-10-15 21:05 EST

Spero Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference

ABUSArbutus2026-10-01 11:30 EST

Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer

MBRXMoleculin Biotech, Inc.2026-09-14 12:35 EST

Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings

View all latest news

Arbutus

Hepatitis B Therapeutics Arbutus Biopharma develops therapies intended to achieve a functional cure for chronic hepatitis B. Its current clinical strategy centers on suppressing viral antigen production with RNA interference. Imdusiran Imdusiran is an RNA interference therapeutic that reduces production of hepatitis B viral proteins,...

Recent company news

ABUSArbutus2026-10-22 11:30 EST

Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor

ABUSArbutus2026-10-01 11:30 EST

Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer

ABUSArbutus2026-09-30 11:30 EST

Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer

ABUSArbutus2026-08-24 11:30 EST

Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share

ABUSArbutus2026-08-21 11:30 EST

Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer

Stock data

Close
3.67 USD
Market cap
841.51M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States